Recently approved recombinant factor VIII (rFVIII) for the replacement treatment in patients with hemophilia A in Italy

Roggeri, Daniela Paola; Zanon, Ezio; Roggeri, Alessandro

doi:10.7175/fe.v18i1.1321

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an Italian study published in 2017, the prescribed IUs of the different rFVIII products analyzed were estimated based on the summaries of product characteristics and not from the data of real-world patients with hemophilia A [39]. Another Italian cost-effectiveness study concluded that, compared with SHL products, the EHL efmoroctocog alfa would produce savings and an increase in quality-adjusted life years (QALY) [40].…”

Section: Discussionmentioning

confidence: 99%

Cost of patients with hemophilia A treated with standard half-life or extended half-life FVIII in Spain

Kim

Peral

Rubio-Rodríguez

et al. 2020

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Background: In a real-world analysis (RWA) conducted in the United States (US), median international units (IUs) of extended half-life (EHL) recombinant coagulation factor VIII (rFVIII) dispensed were 10% to 45% greater than standard half-life (SHL) rFVIII. The mean IUs of each rFVIII dispensed quarterly were obtained from two databases (N = 776). Methods: A probabilistic model in a 1-year time horizon was used in order to analyze the cost comparison of SHL and EHL rFVIII products in Spain. In this analysis, mean IUs were those of the RWA, and frequency of use and prices for each rFVIII were obtained from sales estimates based on Spanish sources (IQVIA; €, 2019) Results: Data showed an average annual savings per patient of €11,227 for SHL rFVIII versus EHL rFVIII products, with a savings probability of 75.5%. The results were stable in the sensitivity analyses. Not switching treatment from SHL to EHL rFVIII resulted in greater savings per patient (€53,078), with a savings probability of 99.9%. Considering the frequency of rFVIII dispensation in the US, annual savings per patient would increase to €16,350 in Spain, with a savings probability of 79.9%. Conclusions: According to this model, use of SHL rFVIII versus EHL rFVIII products could lead to savings for the Spanish National Health System.

show abstract

Section: Discussionmentioning

confidence: 99%